"Designing Growth Strategies is in our DNA"

Gene Editing Market Size, Share & Industry Analysis, By Technologies (CRISPR, Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), Others), By Products (Cell Lines, Reagents & Consumables, Others), By Applications (Drug Discovery & Development, Diagnostics, Genetic Engineering), By End-Users (Pharmaceutical & Biotechnology Companies, Academics & Research Institutes) And Regional Forecast 2022-2029

Region : Global | Report ID: FBI104463 | Status : Ongoing

 

KEY MARKET INSIGHTS

Gene editing involves the tools and techniques that make extremely definite changes in the DNA sequence of a gene in a living organism, fundamentally modifying its genetic blueprints. In contrast to genetic engineering that haphazardly integrates genetic material into a host genome, gene editing aims to make changes in target specific locations. Growing preference for personalized medicine, an increase in R&D expenditure and growth of biotechnology and pharmaceutical industries, rapid advancements in sequencing and Genome Editing technologies, and escalation in the use of products derived from genetically modified organisms are some of the factors propelling the growth of the genome editing market.


Gene editing has indicated good potential for the treatment of genetic disorders, infectious diseases, and cancer. Moreover, an increase in private and public partnership and technological advancements such as Clustered Regularly Interspace Short Palindromic Repeats (CRISPR/Cas9) are further driving the growth of the market. According to the journal of cellular biochemistry, the CRISPR-Cas9 technique has become an essential technology for targeted genome editing within many diverse organisms including bacteria, yeast, zebrafish, mosquitoes, mouse, and mammals. The overall growth of the market can be attributed to the rise in finance for genomic research both in emerging and industrialized nations, development of ingenious gene rearrangement techniques, rising transmittable diseases, increasing contribution in research and development activities, a generous provision from the governments, escalation in the incidence of genetic disorders and cancer.


However, ethical issues concerning the use of gene editing among people and its acceptance are the significant factors obstructing the growth of the market.


Key Market Driver -

Significant potential of the gene editing for the treatment of genetic disorders, infectious diseases, & cancer and technological advancement are projected to boost the market

Key Market Restraint -

Ethical issues concerning the use of gene editing is likely to hinder the market growth.


Market Segmentation:


The global gene editing market can be segmented on the basis of technologies, products, applications, end-users, and region. Based on the technologies, the market can be segmented into clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZFN), and others. Based on the product, the market can be segmented into cell lines, reagents & consumables, and others. Based on the applications, the market can be segmented into drug discovery & development, scientific research, biotechnology, and cell line editing. Based on the end-users, the market can be segmented into pharmaceutical & biotechnology companies, academics & government Research Institutes, and clinical research organizations.


Geographically, the gene-editing market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.


Key Players Covered:


The major companies in the global gene editing report include New England Biolabs, Lonza, Thermo Fisher Scientific Inc., Twist Bioscience, Integrated DNA Technologies, Inc. Merck KGaA, OriGene Technologies Inc., Sangamo Therapeutics, Horizon Discovery Ltd, Intellia Therapeutics Inc., Caribou Biosciences Inc., Transposagen Biopharmaceuticals Inc., GenScript, CRISPR, and other prominent players.


Key Insights:



  • Key Industry Developments - Mergers, Acquisitions, and Partnerships

  • Recent Gene Editing Research & Development Activities

  • Pipeline Analysis of CRISPER/Cas9

  • Introduction of New Products/Approvals (By Major Players)


Regional Analysis:


Geographically, the gene-editing market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is likely to hold the largest share of the market and is anticipated to follow the same thrust over the forecast period owing to the increasing expenditure in research and strong growth in the biotechnology and pharmaceutical industries. The United States is expected to witness the highest growth due to the abundance of world-class research universities and biotechnology industries. Europe is projected to be the second most productive market throughout the forecast period. The technological advancements and partnership activities of pharmaceutical and biotechnology companies are likely to boost the growth of the gene-editing market in this region. However, emerging economies of Asia-Pacific and Latin America possess the high market potential for the growth of the market due to an increase in R&D expenditure, expansion in gene editing companies, and a rising number of laboratories. The Middle East & Africa are expected to show moderate growth during the forecast period.


To gain extensive insights into the market, Request for Customization


Segmentation






























 ATTRIBUTE


  DETAILS

By Technologies




  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)

  • Transcription Activator-Like Effector Nuclease (TALEN)

  • Zinc Finger Nuclease (ZFN)

  • Others



By Products




  • Cell Lines

  • Reagents & Consumables

  • Others



By Applications




  • Drug Discovery & Development

  • Diagnostics

  • Genetic Engineering

  • Cell Line Editing

  • Others



By End-Users




  • Pharmaceutical & Biotechnology Companies

  • Academics & Research Institutes

  • Clinical Research Organizations



By Geography




  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)



Gene Editing Market Industry Developments



  • In September 2018, Thermo Fisher Scientific Inc. had licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to reinforce its genome editing intellectual property (IP) portfolio. Under the terms of the licenses, Thermo Fisher Scientific Inc. is granted global non-exclusive rights to products, tools, and services for research.

  • In January 2015, Novartis signed a collaboration and licensing agreement with Intellia Therapeutics Inc. for the discovery and development of new medicines using CRISPR genome editing technology and Caribou Biosciences Inc. for the development of drug discovery tools. Intellia and Caribou are two of the leading biotechnology companies developing this novel technology


  • Ongoing
  • 2021
  • 2018-2020

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Lek
Jubilant
Styker
Siemens Healthineers
Galemed

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X